Long-term Results of Reduced-fluence Photodynamic Therapy Combined with Intravitreal Anti-Vascular Endothelial Growth Factor for Polypoidal Choroidal Vasculopathy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Han, Ji Yun | - |
dc.contributor.author | Kim, Seong-Woo | - |
dc.contributor.author | Oh, Jaeryung | - |
dc.date.accessioned | 2021-09-03T05:36:16Z | - |
dc.date.available | 2021-09-03T05:36:16Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2017-06 | - |
dc.identifier.issn | 0378-6471 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/83289 | - |
dc.description.abstract | Purpose: To evaluate the long-term effects of reduced-fluence photodynamic therapy (RF-PDT) combined with intravitreal anti-vascular endothelial growth factor (anti-VEGF) for polypoidal choroidal vasculopathy (PCV). Methods: Twenty-two eyes of 21 patients with PCV that were followed up for more than 24 months after RF-PDT and anti-VEGF combination therapy were retrospectively reviewed. The patients received intravitreal anti-VEGF (bevacizumab 1.25 mg, ranibizumab 0.5 mg, or aflibercept 2.0 mg) within 7 days of PDT. Patients were retreated with either RF-PDT and anti-VEGF injection, or with only anti-VEGF injection, as indicated. The main outcome measures were best-corrected visual acuity (BCVA) and central foveal thickness (CFT), which were measured before and after combination therapy. Results: During follow-up, the mean logMAR BCVA significantly improved from 0.75 at baseline to 0.54 at 12 months and 0.52 at 24 months (p = 0.009 and p = 0.032, respectively). The mean CFT significantly decreased from 409.8 mu m at baseline to 234.1 mu m at 12 months and 245.9 mu m at 24 months (p < 0.001 and p = 0.001, respectively). In 20 eyes (90.9%), the BCVA remained stable or improved. Conclusions: The efficacy of this combination therapy for 24 months resulted in stabilized vision and anatomical improvement. RF-PDT combined with intravitreal anti-VEGF injection could be an effective treatment modality for patients with PCV. | - |
dc.language | Korean | - |
dc.language.iso | ko | - |
dc.publisher | KOREAN OPHTHALMOLOGICAL SOC | - |
dc.title | Long-term Results of Reduced-fluence Photodynamic Therapy Combined with Intravitreal Anti-Vascular Endothelial Growth Factor for Polypoidal Choroidal Vasculopathy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Oh, Jaeryung | - |
dc.identifier.doi | 10.3341/jkos.2017.58.6.646 | - |
dc.identifier.wosid | 000471818700004 | - |
dc.identifier.bibliographicCitation | JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY, v.58, no.6, pp.646 - 652 | - |
dc.relation.isPartOf | JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY | - |
dc.citation.title | JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY | - |
dc.citation.volume | 58 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 646 | - |
dc.citation.endPage | 652 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002229849 | - |
dc.description.journalClass | 2 | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Ophthalmology | - |
dc.relation.journalWebOfScienceCategory | Ophthalmology | - |
dc.subject.keywordAuthor | Polypoidal choroidal vasculopathy | - |
dc.subject.keywordAuthor | Reduced fluence photodynamic therapy | - |
dc.subject.keywordAuthor | Vascular endothelial growth factor | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.